DelveInsight’s, “Chronic Myelomonocytic Leukaemia Pipeline Insight 2024” report provides comprehensive insights about 22+ companies and 25+ pipeline drugs in Chronic Myelomonocytic Leukaemia pipeline landscape. It covers the Chronic Myelomonocytic Leukaemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myelomonocytic Leukaemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Chronic Myelomonocytic Leukaemia Research. Learn more about our innovative pipeline today! @ Chronic Myelomonocytic Leukaemia Pipeline Outlook
Key Takeaways from the Chronic Myelomonocytic Leukaemia Pipeline Report
Stay informed about the cutting-edge advancements in Chronic Myelomonocytic Leukaemia Treatments. Download for updates and be a part of the revolution in cancer care @ Chronic Myelomonocytic Leukaemia Clinical Trials Assessment
Chronic Myelomonocytic Leukaemia Emerging Drugs Profile
Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. Currently, the drug is in Phase III stage of development for the treatment of Chronic Myelomonocytic Leukaemia.
Ruxolitinib (Jakafi) is a first-in-class inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2. The result of this inhibition is disruption of cytokine and growth factor signaling pathways, leading to a decrease in proinflammatory cytokines and chemokines. In the clinical study, Ruxoltinib demonstrated meaningful clinical activity in CMML patients with splenomegaly and/or high disease symptom burden. The drug is already approved by the US Food and Drug Administration for the treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF. Jakafi is also indicated for the treatment of people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The drug is currently in Phase II stage of development for the treatment of Chronic Myelomonocytic Leukaemia.
NMS-03592088 (NMS-088) is a potent inhibitor of FLT3, KIT, and CSF1R kinases. NMS-088 is the most active compound among the FLT3 comparators, a finding especially evident in the presence of the FLT3 “gatekeeper mutation,” which is associated with clinical resistance to treatment with other FLT3 inhibitors. There is a rationale for the use of the molecule in Chronic Myelomonocytic Leukemia (CMML) on the basis of the demonstrated inhibition of CSF1R, a highly expressed and activated target in this tumor type. The drug is currently in the Phase I/II stage of development for the treatment of CMML.
LP-108 is a proto-oncogene protein (c-bcl-2) inhibitor. The drug is currently in Phase I stage of development for the treatment of CMML.
Learn more about Chronic Myelomonocytic Leukaemia Drug opportunities in our groundbreaking Chronic Myelomonocytic Leukaemia Research and development projects @ Chronic Myelomonocytic Leukaemia Unmet Needs
Chronic Myelomonocytic Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Chronic Myelomonocytic Leukaemia Products have been categorized under various Molecule types such as
Discover the latest advancements in Chronic Myelomonocytic Leukaemia Treatment by visiting our website. Stay informed about how we’re transforming the future @ Chronic Myelomonocytic Leukaemia Market Drivers and Barriers, and Future Perspectives
Chronic Myelomonocytic Leukaemia Companies and Therapies
Scope of the Chronic Myelomonocytic Leukaemia Pipeline Report
For a detailed overview of our latest research findings and future plans, read the full details of Chronic Myelomonocytic Leukaemia Pipeline on our website @ Chronic Myelomonocytic Leukaemia Drugs and Companies
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/